LUNGHealthcare · Medical DevicesThe 5 Wall Street analysts covering Pulmonx Corp. hold a median 12-month price target of $4 — +33.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Pulmonx Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (95): Analysts have, on balance, been raising their forecasts.
Volatility (22): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on LUNG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +33.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | Stifel | Maintains | Buy | $2.50 → $4.00 |
| 30 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 30 Apr 2026 | D. Boral Capital | Maintains | Buy | $14 |
| 5 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 5 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 20 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 13 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 Oct 2025 | Lake Street | Maintains | Buy | — |
| 8 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 1 Aug 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 31 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 31 July 2025 | Lake Street | Maintains | Buy | — |
| 31 July 2025 | Piper Sandler | Downgrade | Neutral | — |
| 31 July 2025 | Stifel | Maintains | Buy | — |
| 22 May 2025 | Citigroup | Maintains | Neutral | — |
| 1 May 2025 | Canaccord Genuity | Maintains | Buy | — |
| 1 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 1 May 2025 | Piper Sandler | Reiterates | Overweight | — |
| 11 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LUNG appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Pulmonx Corp. returned +70.7% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 60% of US stocks
Cheaper than 24% of US stocks
Cheaper than 78% of US stocks
Higher than 43% of US stocks
Higher than 89% of US stocks
Higher than 19% of US stocks
Higher than 10% of US stocks
Higher than 14% of US stocks
Higher than 19% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pulmonx Corp. has a market value of $126.9M and an enterprise value of $133.4M.
Revenue in the twelve months to 30 June 2026: $87.4M. The latest quarter grew 6.2% year on year.
Net income over the same four quarters: −$48.1M, a −55.0% net margin.
Diluted earnings per share, trailing twelve months: $−1.16.
Free cash flow in the twelve months to 30 June 2026: −$30.7M.
Trailing P/E: −2.3×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Pulmonx Corp. employs 296 people — $295K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pulmonx Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Pulmonx (LUNG) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The source says this might drive the stock higher in the near term.
Why it matters — LUNG watchers may note the rating change as a signal of increased optimism about the company’s earnings prospects.
Pulmonx announced that its management will participate in upcoming investor conferences. The excerpt does not provide conference names or dates.
Why it matters — LUNG watchers may note the planned investor outreach, though the excerpt provides no further details about the conferences.
Pulmonx Corporation reported a Q3 loss of $0.19 per share, compared with the Zacks consensus estimate of a $0.26 loss and a $0.34 loss per share a year earlier. The headline also says the company topped revenue estimates.
Why it matters — LUNG watchers may note that the reported per-share loss was smaller than the consensus estimate and the year-ago loss.
Pulmonx reported third-quarter revenue growth and a narrower loss. On its earnings call, the company cited progress rebuilding its U.S. sales organization, controlling expenses and advancing clinical programs.
Why it matters — These updates describe the company’s reported operating performance and efforts to expand its market.
The provided item is a headline identifying a transcript of Pulmonx Corporation’s Q3 2026 earnings call; no call details are included in the excerpt.
Why it matters — LUNG watchers can note that a Q3 2026 earnings-call transcript is the subject, but the supplied text does not convey company results or management commentary.
The 5 Wall Street analysts covering Pulmonx Corp. have a median 12-month price target of $4, with estimates ranging from $2.5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Pulmonx Corp., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulmonx Corp. 89 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Pulmonx Corp. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (95 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +33.1% from the last close, and Ticker Nerd's factor model ranks Pulmonx Corp. 89 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pulmonx Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LUNG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $5 over the next 12 months.
Pulmonx Corp. returned +70.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Pulmonx Corporation is a medical technology company focused on minimally invasive treatments for severe emphysema and other obstructive lung diseases. The company’s core offering is the Zephyr Endobronchial Valve, a bronchoscopic implant designed to reduce lung hyperinflation in patients who are not candidates for, or do not want, surgery.
The most recent item we track (Zacks Investment Research, 30 Oct 2026): "All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy". Pulmonx (LUNG) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The source says this might drive the stock higher in the near term.
Pulmonx Corporation is a medical technology company focused on minimally invasive treatments for severe emphysema and other obstructive lung diseases. The company’s core offering is the Zephyr Endobronchial Valve, a bronchoscopic implant designed to reduce lung hyperinflation in patients who are not candidates for, or do not want, surgery. Pulmonx also provides the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, which support patient evaluation, treatment planning, and clinical decision-making. Its products are used primarily by hospitals and specialty pulmonary centers within interventional pulmonology. Pulmonx serves a global clinical market and positions its portfolio around evidence-based tools that help physicians identify appropriate patients and deliver targeted lung-volume reduction therapy.
CEO Mr. Glendon E. French · 296 employees · United States · https://www.pulmonx.com
